Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Immunity

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 19791734PMCID PMC2935771
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96.

  2011cited by this paper
• Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

  2009cited by this paper
• Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity.

  2009cited by this paper
• Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1

  2008cited by this paper
• Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient

  2008cited by this paper
• Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patients

  2007cited by this paper
• T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.

  2007cited by this paper
• Identification of an HLA‐A24‐restricted cytotoxic T lymphocyte epitope from human papillomavirus type‐16 E6: The combined effects of bortezomib and interferon‐γ on the presentation of a cryptic epitope

  2007cited by this paper
• Identification of a novel NY‐ESO‐1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population

  2007cited by this paper
• Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming

  2007cited by this paper
• Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients

  2006cited by this paper
• Prognostic significance of HLA class I expression in osteosarcoma defined by anti‐pan HLA class I monoclonal antibody, EMR8‐5

  2006cited by this paper
• Regulatory T cells in cancer.

  2006cited by this paper
• Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy

  2006cited by this paper
• NY-ESO-1: review of an immunogenic tumor antigen.

  2006cited by this paper
• Immunosuppressive networks in the tumour environment and their therapeutic relevance

  2005cited by this paper
• Cancer/testis antigens, gametogenesis and cancer

  2005cited by this paper
• CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.

  2005cited by this paper
• Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

  2005cited by this paper
• Identification of HLA-A24-Restricted CTL Epitope from Cancer-Testis Antigen, NY-ESO-1, and Induction of a Specific Antitumor Immune Response

  2004cited by this paper
• Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

  2004cited by this paper
• Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses

  2003cited by this paper
• NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.

  2002cited by this paper
• Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

  2002cited by this paper
• Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.

  2002cited by this paper
• Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues

  2001cited by this paper
• Topoisomerase I Inhibitors with an Indolocarbazole Structure Transporter as a Transporter of NB-506 and J-107088 , Resistance / Placenta-Specific , ATP-binding Cassette Identification of Breast Cancer Resistant Protein / Mitoxantrone Updated

  2001cited by this paper
• Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

  2000cited by this paper
• Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

  1999cited by this paper
• Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events.

  1999cited by this paper
• Humoral immune responses of cancer patients against “Cancer‐Testis” antigen NY‐ESO‐1: Correlation with clinical events

  1999cited by this paper
• A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens

  1998cited by this paper
• A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.

  1998cited by this paper
• A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.

  1997cited by this paper
• Phenotypic Analysis of Antigen-Specific T Lymphocytes

  1996cited by this paper
• Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene

  1994cited by this paper

• The therapeutic potential value of Cancer-testis antigens in immunotherapy of gastric cancer.

  2022cites this paper
• Spontaneous regressions in non-small cell lung cancer with different clinical outcomes

  2022cites this paper
• A Complete Spontaneous Regression of Lung Cancer with Variations in Size over 38 Months

  2019cites this paper
• Serum Antibody against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer.

  2019cites this paper
• Presence of few PD‐1‐expressing tumor‐infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non‐small cell lung cancer: An exploratory case series

  2018cites this paper
• Research progress of self-assembled nanogel and hybrid hydrogel systems based on pullulan derivatives

  2018cites this paper
• Partial spontaneous remission of small cell lung carcinoma with neurologic symptom

  2017cites this paper
• Spontaneous Regression of Epithelioid Angiosarcoma in a Young Woman

  2017cites this paper
• Austin Oncology Case Reports Complete Remission and Extended Survival in a Patient with Recurrent and Metastatic Non-Small Cell Lung Cancer-A Case Report

  2017cites this paper
• Complete Remission and Extended Survival in a Patient with Recurrent and Metastatic Non-Small Cell Lung Cancer - A Case Report

  2017cites this paper
• Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

  2015cites this paper
• Current advances in self-assembled nanogel delivery systems for immunotherapy.

  2015cites this paper
• Spontaneous regression of non-small cell lung cancer after biopsy of a mediastinal lymph node metastasis: a case report

  2015cites this paper
• Epithelioid angiosarcoma of the skin with spontaneous regression

  2013cites this paper
• NY-ESO-1 antibody as a novel tumour marker of gastric cancer

  2013influential citation
• Diagnostic Biopsy Does Not Commonly Induce Intratumoral CD8 T Cell Infiltration in Merkel Cell Carcinoma

  2012cites this paper
• Complete spontaneous regression of non-small cell lung cancer followed by adrenal relapse.

  2011cites this paper
• Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients

  2010cites this paper
• Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti–Programmed Cell Death-1 Therapy in NSCLC

  year unknowncites this paper